oral non-peptide GLP-1R GPCR partial agonist in Ph. I for Type 2 diabetes, HV study complete from cell-based screen and opt. PNAS Nov. 11, 2020 Chugai, Shizuoka, JP / Eli Lilly, Indianapolis, IN